Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Up 205.1% in August

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a large increase in short interest in August. As of August 14th, there was short interest totaling 51,809 shares, an increase of 205.1% from the July 30th total of 16,980 shares. Approximately 1.2% of the company’s stock are sold short. Based on an average trading volume of 11,844,452 shares, the short-interest ratio is currently 0.0 days.

Insider Activity

In other news, major shareholder Financial Lp Hrt sold 34,938 shares of the stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $1.40, for a total value of $48,913.20. Following the completion of the sale, the insider directly owned 92,055 shares of the company’s stock, valued at $128,877. This represents a 27.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BJDX has been the subject of several research reports. Wall Street Zen upgraded Bluejay Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Bluejay Diagnostics presently has an average rating of “Sell”.

Bluejay Diagnostics Stock Performance

Shares of BJDX traded up $0.02 during mid-day trading on Thursday, hitting $0.91. The company’s stock had a trading volume of 144,313 shares, compared to its average volume of 2,361,801. The firm has a market capitalization of $4.07 million, a PE ratio of -0.13 and a beta of 0.89. The stock’s 50-day moving average is $1.48 and its two-hundred day moving average is $2.06. Bluejay Diagnostics has a one year low of $0.83 and a one year high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.12) EPS for the quarter, beating analysts’ consensus estimates of ($3,520.00) by $3,518.88.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.